Holen Sie sich die Stockscreener-App
0.365
6.29%
-0.02
Reviva Pharmaceuticals Holdings Inc Aktie (RVPH) Neueste Nachrichten
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Rating of “Buy” by Brokerages - Defense World
Ameriprise Financial Inc. Takes $84,000 Position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
RVPH: Open Label Extension Results & Key Opinion Leader Discussion - MSN
Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - GlobeNewswire
Late-Stage CNS Drug Developer Reviva Pharma Reveals New Pipeline Updates at Major Neuroscience Conference - Stock Titan
Data Readout Positive from Trial of New Schizophrenia Drug - streetwisereports.com
Reviva Pharmaceuticals (NASDAQ:RVPH) Receives Buy Rating from D. Boral Capital - Defense World
Reviva Pharmaceuticals (RVPH) Receives Buy Rating from D. Boral - GuruFocus
Reviva reports positive year-long schizophrenia drug study By Investing.com - Investing.com South Africa
Reviva Pharmaceuticals Holdings, Inc. Announces Positive Full Dataset for 1-Year Phase 3 Recover Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - MarketScreener
Reviva Reports Positive Full Dataset For Phase 3 RECOVER OLE Study Of Brilaroxazine In Schizophrenia - Nasdaq
Reviva reports positive year-long schizophrenia drug study - Investing.com Australia
Reviva Pharmaceuticals (RVPH) Unveils Promising Phase 3 Brilaroxazine Study Results | RVPH Stock News - GuruFocus
Reviva Pharmaceuticals Completes Phase 3 Study for Schizophrenia - TipRanks
Reviva Pharmaceuticals Reports Positive 1-Year Phase 3 Results for Brilaroxazine in Schizophrenia, Highlighting Efficacy and Safety - Nasdaq
Reviva Announces Positive Full Dataset for 1-Year Phase 3 - GlobeNewswire
Breakthrough in Schizophrenia Treatment: Phase 3 Trial Reveals Sustained Efficacy Over 12 Months - Stock Titan
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Shares Sold by Millennium Management LLC - Defense World
Reviva Pharmaceuticals Launches $50M At-Market Offering - TipRanks
Reviva Pharmaceuticals Holdings IncEnters Into At Market Issuance Sales AgreementSEC Filing - marketscreener.com
What is Zacks Small Cap’s Estimate for RVPH Q2 Earnings? - Defense World
Roth Capital Issues Positive Forecast for RVPH Earnings - Defense World
D. Boral Capital Lowers Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target to $3.00 - Defense World
Reviva Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Reviva stock target cut to $3 on cash concerns, retains Buy rating - Investing.com Australia
Spotify To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday - NewsBreak: Local News & Alerts
Reviva to Participate in Upcoming Investor Conferences in May 2025 - GlobeNewswire
Late-Stage CNS Drug Developer Reviva Opens Access to Management at Benchmark and Lytham Conferences - Stock Titan
Reviva Pharmaceuticals (RVPH): Analyst Maintains Buy Rating, Low - GuruFocus
Reviva Pharmaceuticals (RVPH) Sees Price Target Reduction Amid Funding Concerns | RVPH Stock News - GuruFocus
Reviva Pharmaceuticals (RVPH): Analyst Maintains Buy Rating, Lowers Price Target | RVPH Stock News - GuruFocus
Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Reviva Pharmaceuticals (RVPH) Advances Brilaroxazine Program Tow - GuruFocus
Reviva Pharmaceuticals (RVPH) Advances Brilaroxazine Program Towards Approval | RVPH Stock News - GuruFocus
Major Milestone: 446 Patients Complete Reviva's Schizophrenia Drug Trial, Full Results Expected Q2 2025 - Stock Titan
Reviva to Participate in the A.G.P. Healthcare Company Showcase - GlobeNewswire
Tower Research Capital LLC TRC Has $48,000 Stock Holdings in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals (RVPH) Expected to Announce Earnings on Tuesday - Defense World
Short Interest in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Grows By 30.5% - Defense World
Geode Capital Management LLC Grows Position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
Schizophrenia Market to Witness Significant Growth by 2034 Across 7MM as New Therapies Enter Late-Stage Trials | DelveInsight - GlobeNewswire Inc.
Reviva to Participate in the Citizens Life Sciences Conference - GlobeNewswire
Reviva Pharma CEO Takes Center Stage: Key Updates Coming at Major Life Sciences Conference - Stock Titan
Gaining Ground: Reviva Pharmaceuticals Holdings Inc (RVPH) Closes Lower at 0.86, Down -4.98 - DWinneX
Market Update: American Rebel Holdings Inc (AREB) Sees Negative Movement, Closing at 3.85 - DWinneX
Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - ACCESS Newswire
D. Boral Capital Reiterates “Buy” Rating for Reviva Pharmaceuticals (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals Holdings Inc Inc. (RVPH) Price Performance: The Role of Supply and Demand - investchronicle.com
Reviva to Present Late-Breaking Poster on the RECOVER - GlobeNewswire
Major Phase 3 Breakthrough: Reviva Unveils 12-Month Schizophrenia Treatment Data at ASCP 2025 - Stock Titan
Investing in Reviva Pharmaceuticals Holdings Inc (RVPH) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - uspostnews.com
0.34%
7.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):